PRGO Stock Overview
Provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 4/6 |
Perrigo Company plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$27.81 |
| 52 Week High | US$38.07 |
| 52 Week Low | US$24.82 |
| Beta | 0.51 |
| 11 Month Change | -0.68% |
| 3 Month Change | -5.18% |
| 1 Year Change | -26.37% |
| 33 Year Change | -32.00% |
| 5 Year Change | -38.78% |
| Change since IPO | 139.23% |
Recent News & Updates
Perrigo (NYSE:PRGO) Is Due To Pay A Dividend Of $0.276
Aug 21
The Play On Perrigo
Aug 16Perrigo (NYSE:PRGO) Has Announced A Dividend Of $0.276
Aug 07Recent updates
Perrigo (NYSE:PRGO) Is Due To Pay A Dividend Of $0.276
Aug 21The Play On Perrigo
Aug 16Perrigo (NYSE:PRGO) Has Announced A Dividend Of $0.276
Aug 07Improved Revenues Required Before Perrigo Company plc (NYSE:PRGO) Shares Find Their Feet
Jul 03These 4 Measures Indicate That Perrigo (NYSE:PRGO) Is Using Debt Extensively
May 29Benign Growth For Perrigo Company plc (NYSE:PRGO) Underpins Its Share Price
Mar 27These 4 Measures Indicate That Perrigo (NYSE:PRGO) Is Using Debt Extensively
Feb 01The Market Doesn't Like What It Sees From Perrigo Company plc's (NYSE:PRGO) Revenues Yet
Dec 28Perrigo's New Chapter: Its Bold Turnaround Plan Is Worth Buying
Nov 15The Prognosis For Perrigo
Aug 30Perrigo Outlook Healed By Repositioning
Jun 12Perrigo raises dividend by 5% to $0.273/share
Feb 21Perrigo: Still Languishing But Short-Term Trend Offers Encouragement
Jan 18Perrigo Non-GAAP EPS of $0.56 misses by $0.11, revenue of $1.1B misses by $40M, lowers FY adj. EPS guidance
Nov 08Perrigo to invest $170M to expand baby formula manufacturing, buys Nestlé Gateway plant
Nov 01Perrigo Company plc Is Back On Track
Oct 20Perrigo to face FDA AdCom meeting for OTC contraceptive
Sep 12Perrigo responds to 'misleading and inaccurate information' on Zantac claims
Aug 17Perrigo reports Q2 mixed results; raises FY22 organic net sales growth outlook
Aug 09Perrigo declares $0.26 dividend
Aug 02Perrigo: HRA Acquisition To Drive Significant Growth
Jul 20Perrigo unit seeks FDA over-the-counter approval for birth control pill Opill
Jul 11Perrigo: The Longer The Base The Higher In Space
Apr 12The Prognosis For Perrigo
Jan 09Perrigo: Honing In On A Long Term Bottom
Dec 16Shareholder Returns
| PRGO | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 3.8% | 2.3% | 3.1% |
| 1Y | -26.4% | 17.4% | 25.4% |
Return vs Industry: PRGO underperformed the US Pharmaceuticals industry which returned 16% over the past year.
Return vs Market: PRGO underperformed the US Market which returned 25.6% over the past year.
Price Volatility
| PRGO volatility | |
|---|---|
| PRGO Average Weekly Movement | 3.9% |
| Pharmaceuticals Industry Average Movement | 10.4% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.0% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: PRGO has not had significant price volatility in the past 3 months.
Volatility Over Time: PRGO's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1887 | 9,140 | Patrick Lockwood-Taylor | www.perrigo.com |
Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers.
Perrigo Company plc Fundamentals Summary
| PRGO fundamental statistics | |
|---|---|
| Market cap | US$3.77b |
| Earnings (TTM) | -US$113.80m |
| Revenue (TTM) | US$4.43b |
0.9x
P/S Ratio-33.3x
P/E RatioIs PRGO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PRGO income statement (TTM) | |
|---|---|
| Revenue | US$4.43b |
| Cost of Revenue | US$2.84b |
| Gross Profit | US$1.59b |
| Other Expenses | US$1.70b |
| Earnings | -US$113.80m |
Last Reported Earnings
Jun 29, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.83 |
| Gross Margin | 35.93% |
| Net Profit Margin | -2.57% |
| Debt/Equity Ratio | 89.2% |
How did PRGO perform over the long term?
See historical performance and comparisonDividends
4.0%
Current Dividend Yield-131%
Payout RatioDoes PRGO pay a reliable dividends?
See PRGO dividend history and benchmarks| Perrigo dividend dates | |
|---|---|
| Ex Dividend Date | Aug 30 2024 |
| Dividend Pay Date | Sep 17 2024 |
| Days until Ex dividend | 8 days |
| Days until Dividend pay date | 26 days |
Does PRGO pay a reliable dividends?
See PRGO dividend history and benchmarks